A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date12/11/0211/30/05

Funding

  • GlaxoSmithKline: $34,679.00